Life Sciences Tools and Services(IN20268.HK)

Last Updated 08:00:00
longbridge loading
Company Encyclopedia
View More
name
Life Sciences Tools and Services
IN20268.HK
News
View More

Pharmaron Beijing Files HKEX Disclosure on Share Capital Increase to 1,476,658,400 Shares at Undisclosed Price

Pharmaron Beijing Co. Ltd. has filed a disclosure with the Hong Kong Stock Exchange regarding the issuance of 81,643 new A shares to employees under its 2021 Restricted A Share Incentive Scheme. The shares were issued at a price of RMB 30.39 each, increasing the total share capital to 1,476,658,400 shares. This announcement is part of the company's ongoing incentive program for employees.

Reuters·
HK
03759
0.00%
SH
513700
+1.34%
Reuters·
HK
03759
0.00%
SH
513700
+1.34%

Xtalpi Holdings Completes HK$2.87 Billion Zero Coupon Convertible Bond Issue

XtalPi Holdings Ltd. has successfully completed the issuance of HK$2.87 billion in zero coupon convertible bonds due in 2027. All conditions for the bond issuance have been met, and the transaction is finalized. The bonds are not registered under the U.S. Securities Act and will not be publicly offered in the United States.

Reuters·
HK
02228
-1.11%
Reuters·
HK
02228
-1.11%

Zhejiang Taimei Medical Technology Co. Ltd. Announces Date for First Extraordinary General Meeting

Zhejiang Taimei Medical Technology Co. Ltd. will hold its first extraordinary general meeting on February 14, 2026, at Technology Oasis Phase 3, Shanghai. Shareholders will vote on the adoption of the 2026 H Share Award Scheme and conditional award grants to specific directors and executives. This announcement was published via the Issuer Information Service of the Hong Kong Stock Exchange.

Reuters·
HK
02576
+3.85%
Reuters·
HK
02576
+3.85%

Zhejiang Taimei Medical Technology Proposes 2026 H Share Award Scheme and Initial Grants

Zhejiang Taimei Medical Technology Co., Ltd. has proposed a 2026 H Share Award Scheme, pending shareholder approval. The board conditionally approved initial grants of 20,042,494 share awards to 63 participants, including directors and key employees, to retain talent and align interests with shareholders. The stock currently holds a Hold rating with a price target of HK$4.50. The company focuses on digital solutions in the healthcare sector and aims for long-term growth through equity-based compensation.

Tip Ranks·
HK
02576
+3.85%
Tip Ranks·
HK
02576
+3.85%

Insilico and Qilu Pharmaceutical sign deal for cardiometabolic therapies

Insilico Medicine and Qilu Pharmaceutical have signed a $120 million deal to develop cardiometabolic therapies using Insilico’s Pharma.AI platform. The agreement includes milestone payments and royalties based on net sales. Insilico will design small molecules for metabolic disorders, while Qilu will handle development and commercialization. This collaboration builds on Qilu's previous adoption of Insilico's PandaOmics in 2021. Insilico's CEO expressed optimism about the potential of AI in accelerating drug innovation for cardiometabolic diseases.

Pharmaceutical Technology·
HK
03696
-1.65%
Pharmaceutical Technology·
HK
03696
-1.65%
Posts
View More

$XTALPI(02228.HK) Watching the neighboring KuKuKu... rising, it's really envy. md

Envy is about to strike. What to do

Notification from groland: Currently, there are 51 successful applicants for the experience officer (due to the same time for the last two).

*To protect everyone's personal privacy, we only publish the...

  • 0

$XTALPI(02228.HK) can only marvel at MM's absolute control over the stock price. The key is still holding the chips. I feel like I need to study the current short-selling data.

$XTALPI(02228.HK) During the meeting, the preset order was filled, very happy it's all money. Treating Kai to lunch at noon!

  • 0
© 2026 Longbridge｜Disclaimer